Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease

Ann Intern Med. 1981 Mar;94(3):404-5. doi: 10.7326/0003-4819-94-3-404.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Kidney Injury / drug therapy
  • Calcifediol
  • Calcitriol
  • Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy*
  • Chronic Kidney Disease-Mineral and Bone Disorder / prevention & control
  • Dihydroxycholecalciferols / adverse effects
  • Dihydroxycholecalciferols / metabolism
  • Dihydroxycholecalciferols / therapeutic use
  • Humans
  • Hydroxycholecalciferols / adverse effects
  • Hydroxycholecalciferols / metabolism
  • Hydroxycholecalciferols / therapeutic use*
  • Hypercalcemia / chemically induced
  • Osteomalacia / drug therapy
  • Renal Dialysis
  • Risk
  • Uremia / complications
  • Uremia / drug therapy*

Substances

  • Dihydroxycholecalciferols
  • Hydroxycholecalciferols
  • Calcitriol
  • Calcifediol